Lowering Covid-19 cases is the best thing US can do to improve chances that vaccines will continue working, expert says
Lowering Covid-19 cases across the US isn’t only critical to helping prevent another surge fueled by variants — it also makes vaccines more likely to continue working effectively against mutations, one expert says.
“The best thing we could possibly do to improve the chances that the vaccine will continue working … is to reduce cases as much as possible without having those reductions occur as a result of vaccine-derived immunity,” Dr. Michael Mina, an epidemiologist and immunologist at the Harvard T.H. Chan School of Public Health, said Tuesday.
The US on Tuesday reported more than 59,500 new Covid-19 cases — a far cry from the six-figure case totals a month ago. Johns Hopkins University has reported more than 66,500 new cases so far Wednesday.
But experts warn these infection numbers are still high and could lead to another uptick if Americans let down their guard.
This is why measures like masks and social distancing continue to play a key role, because if the virus continues circulating at high levels, it will likely more often come into contact with, and try to infect, people who have been vaccinated, Mina said.
“The more opportunities we give the virus to come in contact with somebody who is immune, the more opportunities there are for the virus to find a way around that level of immunity and those antibodies,” Mina added.
Pfizer, Moderna vaccines can protect against variant, new report says
A new report in the New England Journal of Medicine on Wednesday suggests Pfizer-BioNTech’s Covid-19 vaccine offers protections against concerning new coronavirus variants, including one first seen in South Africa called B.1.351.
For the study, which was reported in the New England Journal of Medicine, researchers at Pfizer and the University of Texas Medical Branch genetically engineered versions of the virus to carry some of the mutations found in B.1.351. They tested them against blood samples taken from 15 people who had received two doses of the Pfizer/BioNTech vaccine as part of a clinical trial.
While blood serum samples produced less neutralizing antibody activity, it was still enough to neutralize the virus, the researchers wrote in the letter to the journal. This is in line with other studies — and well within what’s seen with other viruses, one researcher said.
“Although we do not yet know exactly what level of neutralization is required for protection against Covid-19 disease or infection, our experience with other vaccines tells us that it is likely that the Pfizer vaccine offers relatively good protection against this new variant,” Scott Weaver, director of the Institute for Human Infections and Immunity at the University of Texas Medical Branch and an author of the study, told CNN Wednesday.
Pfizer said there is no evidence in real life that the variant escapes the protection offered by its vaccine.
“Nevertheless, Pfizer and BioNTech are taking the necessary steps, making the right investments, and engaging in the appropriate conversations with regulators to be in a position to develop and seek authorization for an updated mRNA vaccine or booster once a strain that significantly reduces the protection from the vaccine is identified,” Pfizer said in a statement.
Dr. Ashish Jha, dean of the Brown University School of Public Health, called the findings “unabashedly good news.”
“Time after time, study after study shows that our vaccines look like they’re going to hold up pretty well, certainly against the UK variant, and then the new studies showing that it’s goin to hold up pretty well against the South Africa variant,” Jha told CNN Wednesday.
Separately, a team at the National Institutes of Health and Moderna published a letter in the same journal outlining findings from an experiment they reported last month. They also reported a reduction in the antibody response to viruses genetically engineered to look like the B.1.351 variant — but not enough of a reduction to make the vaccine work any less effectively.
“Despite this reduction, neutralizing titer levels with (the variant discovered in South Africa) remain above levels that are expected to be protective,” the company said in a statement.
Researchers found no reduction in efficacy against B.1.1.7 strain, the variant first seen in the UK.
Scientists have identified several variants circulating in the US and are particularly worried about the highly contagious B.1.1.7 strain. One study found cases of the variant are rapidly increasing across the US and significant community transmission may be occurring.
More than 1,270 cases of the variant have been reported across 41 states and Washington, DC, according to data from the Centers for Disease Control and Prevention. Roughly a third are in Florida, the CDC data show.
But the agency has said that likely doesn’t represent the total nationwide and it has recently ramped up its genome sequencing efforts to identify variants.
Variants could lead to a rapid rise in the numbers of Covid-19 cases, according to two new CDC reports.
In one report released Wednesday, researchers from the CDC and the Minnesota health department detailed cases of the B.1.1.7 variant.
The CDC’s Morbidity and Mortality Weekly Report described B.1.1.7 cases in specimens collected from eight Minnesota residents, ages 15 to 41, from mid-December through mid-January. Five reported Covid-19-like symptoms and three were asymptomatic.
Three of the people had a history of international travel in the two weeks before they became ill, including two who traveled in West Africa and one who traveled to the Dominican Republic. Three others had traveled to California, including one who received a positive test while in California and isolated before returning to Minnesota. None had a history of travel to the UK.
Identification of the variants in Minnesota “highlights the importance of mitigation measures such as mask use, physical distancing, avoiding crowds and poorly ventilated indoor spaces, isolation of persons with diagnosed COVID-19, quarantine of close contacts of persons with COVID-19, and adherence to CDC travel guidance,” according to the report.
In a separate CDC report also released Wednesday, researchers from Zambia described how the detection of the B.1.351 variant first identified in South Africa coincided with a rapid rise of cases in Zambia — and this variant might have become the dominant strain there.
On Tuesday, Quest Diagnostics announced it was also sequencing tests to support the CDC’s efforts to track mutations, adding that the company had already doubled the amount of genomic sequencing it started performing last month.
Fauci shifts vaccine timeline for Americans
The US is also facing challenges on the vaccine front.
More than 39 million people have received at least the first dose of a Covid-19 vaccine, according to CDC data. About 15 million people — roughly 4.5% of the US population — have been fully vaccinated, the data shows.
Dr. Anthony Fauci told CNN on Tuesday it could now be early June before vaccines are available to the general population — shifting the timeline from previous estimates around the end of April.
“That was predicated on (the Johnson & Johnson vaccine) having considerably more doses than now we know they’re going to have,” Fauci said.
CNN has learned that if it gets the green light from the Food and Drug Administration, the rollout of the Johnson & Johnson vaccine will be slower than officials initially expected.
The administration expects single-digit millions of doses for the vaccine if it’s authorized for emergency use. However, due to a miscommunication over the production timeline, government officials thought that the number would ramp up to between 20 or 30 million doses by April. But now, they’re expecting fewer than 20 million doses in April, an administration official told CNN.
“Essentially they’re going to come through with a contractual agreement of getting 100 million doses by a certain period of time, except it will be heavily loaded toward the latter part of that time, as opposed to immediately after they get their EUA,” or emergency use authorization, Fauci told CNN’s Anderson Cooper on Wednesday.
Separately, President Joe Biden promised on Tuesday that 600 million Covid-19 vaccine doses would be available to the country by the end of July, “enough to vaccinate every single American.”
The President’s promise follows his announcement earlier this month that the US will have enough vaccines for 300 million Americans by the end of July, with the help of additional vaccine purchases the government made from Pfizer and Moderna.
Getting everyone vaccinated who wants to be may take “an additional couple of months,” Fauci said Wednesday, and it may be “toward the end of the summer to get everybody vaccinated,” Fauci said.
As much as 85% of the population may need to be vaccinated to achieve herd immunity, Fauci said, but that’s only an estimate, because no one knows what percentage is needed to meet that goal with the novel coronavirus.
More vaccine challenges: inequity, weather and short supply
Among the other difficulties the US is working to overcome is inequity in vaccine distribution, frigid weather and a short supply.
New York City officials said Tuesday they were working to combat Covid-19 vaccine disparities, building off of efforts that have focused on outreach to some of the region’s hardest-hit communities.
But newly released data shows “the scale of the challenge in front of us,” said Dr. Torian Easterling, first deputy commissioner and chief equity officer for the city’s health department.
“There’s much smaller proportion of vaccines going to Black and Brown New Yorkers. We see these geographic disparities bearing out as well,” Easterling said, adding that the South Bronx, parts of Central Queens and Central Brooklyn, lag behind in vaccinations.
Meanwhile, the fierce winter storms that have unleashed frigid and dangerous weather conditions have now slowed vaccinations across the country.
